Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
7.17
+0.20 (2.87%)
At close: Mar 13, 2026, 4:00 PM EDT
7.50
+0.33 (4.60%)
After-hours: Mar 13, 2026, 6:59 PM EDT
Alpha Tau Medical Employees
Alpha Tau Medical had 125 employees as of December 31, 2024. The number of employees increased by 4 or 3.31% compared to the previous year.
Employees
125
Change (1Y)
4
Growth (1Y)
3.31%
Revenue / Employee
n/a
Profits / Employee
-$341,016
Market Cap
631.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 125 | 4 | 3.31% |
| Dec 31, 2023 | 121 | 27 | 28.72% |
| Dec 31, 2022 | 94 | 11 | 13.25% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Replimune Group | 479 |
| MeiraGTx Holdings | 409 |
| ProKidney | 204 |
| Prime Medicine | 146 |
| Annexon | 99 |
| Tectonic Therapeutic | 60 |
| AgomAb Therapeutics NV | 58 |
DRTS News
- 4 days ago - Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 17 days ago - HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT - Business Wire
- 18 days ago - Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer - GlobeNewsWire
- 5 weeks ago - Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing - GlobeNewsWire
- 6 weeks ago - Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead - GlobeNewsWire
- 7 weeks ago - Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 - Seeking Alpha
- 2 months ago - Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study - GlobeNewsWire
- 2 months ago - Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - GlobeNewsWire